NCT06789796View on ClinicalTrials.gov

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

636

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2030

Conditions
Small-cell Lung Cancer
Interventions
DRUG

Iparomlimab and Tuvonralimab (QL1706)

5mg/kg , every 3 weeks

DRUG

placebo for QL1604

every 3 weeks

DRUG

QL1604

200mg, every 3 weeks

DRUG

placebo for Iparomlimab and Tuvonralimab (QL1706)

every 3 weeks

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY